Professor Chan Cheah speaks about the phase I clinical trial which looks at the safety and efficacy of the anti-CD20/CD3 bispecific antibody Mosunetuzumab in patients with high-risk Follicular Lymphoma. Overall, treatment with single agent Mosunetuzumab appears to be an encouraging agent in this group of patients and has shown consistently high response rates with an acceptable safety profile similar to other bispecific antibodies.
